Survotitude Research Peptide: Dual GCGR/GLP-1R Agonist for Metabolic Studies

In the evolving field of metabolic research, the development of multi-receptor agonists has opened new frontiers for studying obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). At the forefront of this innovation is Survodutide research peptide (also known as BI 456906) — a novel 29‑amino‑acid, dual agonist of the glucagon receptor (GCGR) and the glucagon‑like peptide‑1 receptor (GLP‑1R). By simultaneously targeting both of these key metabolic pathways, Survotitude offers a unique tool for investigating appetite regulation, energy homeostasis, and hepatic lipid metabolism.

At Wuhan Top Miracle Peptides, we supply high-purity Survotitude research peptide to research institutions, laboratories, and wholesale buyers across the United Kingdom, France, Germany, Spain, Sweden, Italy, and the USA. Every batch is synthesised with GMP‑compliant processes, HPLC‑verified to ≥99% purity, and accompanied by a Certificate of Analysis (COA) — ensuring your research is built on quality, reproducibility, and scientific integrity.

What Makes Survotitude Research Peptide Unique?

Most metabolic research peptides target a single receptor pathway. Survodutide research peptide is different. It is engineered as a dual agonist with a balanced, potent activation of both GCGR and GLP‑1R (EC₅₀ = 0.52 nM and 0.33 nM, respectively, in CHO‑K1 cells). This dual mechanism produces complementary effects:

• GLP‑1R activation – Reduces appetite, delays gastric emptying, and improves blood sugar control via central satiety signalling.

• GCGR activation – Increases energy expenditure, promotes fatty acid oxidation, and reduces hepatic fat accumulation through peripheral and central pathways.

A recent 2026 study published in Molecular Metabolism demonstrated that Survotitude acts through circumventricular organs (CVOs) in the brain, directly accessing satiety‑mediating nuclei without uniformly crossing the blood‑brain barrier. This targeted central action suppresses food intake via GLP‑1R‑dependent pathways, while GCGR‑driven mechanisms enhance energy expenditure — a true dual mode of action for studying complex metabolic phenotypes.

Chemical & Physical Specifications

Understanding the molecular characteristics of Survotitude research peptide is essential for reproducible experimental design. Below are the verified specifications.

The sequence includes a non‑coded amino acid (1‑aminocyclobutane‑1‑carboxylic acid) at position 2 to enhance proteolytic stability, and a C18 fatty diacid moiety conjugated via a glycine‑serine linker to extend half‑life through albumin binding.

A note on spelling: The research community widely recognises this peptide as Survodutide (with a “d”). Some online sources may use the misspelling “Survotitude”. The correct chemical name and CAS number are confirmed by the manufacturer and independent suppliers.

Key Research Applications for Survodutide Research Peptide

Survodutide research peptide has been extensively investigated across multiple areas of metabolic disease research.

 Obesity & Appetite Regulation Research

Survotitude has demonstrated robust, dose‑dependent weight loss in preclinical and clinical models. In the Phase 3 SYNCHRONIZE‑1 trial (NCT06066515), 725 adults with obesity or overweight were treated with weekly subcutaneous Survodutide (3.6 mg or 6.0 mg) for 76 weeks. Results showed mean body weight reductions of 16.6% versus 3.2% with placebo. Up to 85.1% of treated participants achieved ≥5% weight loss, compared to 38.8% in the placebo arm.

Preclinical mechanistic studies have shown that Survodutide’s intake‑suppressive effects are GLP‑1R‑dependent, activating c‑Fos in multiple satiety‑mediating nuclei. The GCGR component complements this by driving energy expenditure, making Survotitude a valuable tool for studying the interplay between appetite and metabolism.

 Metabolic Dysfunction‑Associated Steatohepatitis (MASH) & Hepatic Research

Survodutide’s glucagon co‑agonism directly targets hepatic fat oxidation and fibrosis pathways. A Phase 2 trial in MASH patients with liver fibrosis (stages 2–3) reported:

• ≥65% reduction in liver fat content (MRI‑measured) in the 4.8 mg dose group.

• 63–67% of participants achieved a ≥30% reduction in liver fat.

• 34–36% showed improvement in fibrosis by at least one stage.

These findings highlight Survodutide’s potential as a research tool for studying hepatic lipid metabolism, fibrosis regression, and the pathophysiology of MASH.

 Lean Mass Preservation & Body Composition

Unlike single‑agonist GLP‑1R peptides, Survodutide’s GCGR activation may favour fat‑specific weight loss while sparing lean mass. In preclinical models, lean mass loss was not significantly different between Survotitude and semaglutide treatment (8.3 ± 0.8% vs. 5.3 ± 0.9%, p = 0.9071), indicating that weight reduction was driven primarily by fat loss, not muscle catabolism. This mechanistic distinction is critical for research into sarcopenic obesity and metabolic health.

 Energy Expenditure & Fatty Acid Oxidation

An ongoing Phase 2 trial (NCT06745284) is specifically examining how Survodutide alters energy expenditure and fatty acid oxidation in participants with obesity. The study uses whole‑body calorimetry to measure oxygen consumption and carbon dioxide production, providing direct insights into the metabolic impact of GCGR activation.

 Type 2 Diabetes Research

Survodutide has demonstrated clinically meaningful blood sugar lowering in Phase 2 trials, with efficacy comparable to or exceeding that of selective GLP‑1R agonists. The dual mechanism improves both glucose‑dependent insulin secretion and insulin sensitivity, offering a comprehensive model for studying diabetic pathophysiology and therapeutic strategies.

Survodutide vs. Other Peptide Agonists: A Research Comparison

For researchers, Survodutide offers a distinct advantage: the ability to study both central appetite control (via GLP‑1R) and peripheral energy metabolism (via GCGR) within a single molecular platform.

Reconstitution & Handling Protocol

Survodutide research peptide is supplied as a lyophilised powder and must be reconstituted correctly to maintain its stability and biological activity.

Step 1 – Preparation

• Bring the sealed Survodutide vial and your chosen diluent (sterile bacteriostatic water or sterile PBS, pH 5–7) to room temperature before opening. Condensation can degrade the lyophilised powder.

• Clean your work surface with 70% ethanol and prepare sterile syringes, alcohol wipes, and a clean work mat.

Step 2 – Vial Sanitisation

• Wipe the rubber stoppers of both the Survodutide vial and the diluent vial with a fresh alcohol wipe. Allow the alcohol to evaporate completely before piercing.

Step 3 – Reconstitution

• Draw your desired volume of diluent into a sterile syringe (e.g., 1 mL for a 5 mg vial → 5 mg/mL concentration).

• Insert the needle and slowly inject the diluent against the inner glass wall. Do not spray directly onto the lyophilised powder.

• Gently swirl the vial until the solution is clear and fully dissolved. Do not shake vigorously.

Step 4 – Aliquoting & Storage

• Immediately aliquot the reconstituted peptide into single‑use sterile vials.

• Store aliquots at –20°C. Avoid repeated freeze‑thaw cycles.

• Once thawed, store at 2–8°C and use within 28 days.

Concentration Reference Table

Adjust diluent volume proportionally based on your experimental requirements.

Storage & Stability Guidelines

Quality Assurance & Why Choose Wuhan Top Miracle Peptides

As a licensed peptide supplier in the United Kingdom, we supply Survodutide research peptide with uncompromising quality standards.

• ≥99% purity confirmed by HPLC and mass spectrometry for every batch.

• GMP‑compliant manufacturing in ISO 13485:2016 and GMP‑certified facilities.

• Full traceability with batch‑specific Certificates of Analysis (COA).

• Wholesale pricing – from single vials to bulk orders for research institutions.

• Fast domestic shipping across the UK (London, Manchester, Birmingham, Edinburgh, etc.) and reliable delivery to the EU and USA.

• Research‑use only (RUO) – fully compliant with UK, EU, and international regulations.

Researchers across the United Kingdom trust us for verified purity, transparent documentation, and technical support.

FAQ: Survotitude Research Peptide

 What is Survodutide research peptide?
Survodutide (BI 456906) is a 29‑amino‑acid, dual agonist of the glucagon receptor (GCGR) and GLP‑1 receptor (GLP‑1R). It is used in metabolic research to study obesity, MASH, type 2 diabetes, and energy homeostasis.

 What is the molecular weight of Survodutide?
The molecular weight of the free base is approximately 4,231.62 g/mol. The acylated C18 diacid moiety and linker contribute to its extended half‑life.

 How does Survodutide differ from semaglutide or tirzepatide for research?
Survodutide activates both GCGR and GLP‑1R. This dual mechanism allows researchers to study both appetite suppression (GLP‑1R) and increased energy expenditure / hepatic fat oxidation (GCGR) within a single compound — features not present in selective GLP‑1R agonists.

 Is Survodutide the same as “Survotitude”?
Yes, “Survotitude” is a common misspelling. The correct chemical name and CAS number (2805997‑46‑8) refer to Survodutide. All reputable suppliers and the published literature use Survodutide.

 What purity does your Survodutide meet?
Our Survodutide research peptide is tested to ≥99% purity by HPLC. Each batch is accompanied by a COA with full analytical data.

 How should I reconstitute Survodutide?
Use sterile bacteriostatic water or sterile PBS (pH 5–7). Bring the vial to room temperature, inject the diluent slowly against the inner glass wall, then swirl gently. Do not shake.

 Is Survodutide legal to purchase in the UK for research?
Yes. Survotitude is a laboratory reagent sold for research use only (RUO). It is fully legal to purchase, possess, and use in the UK for legitimate in‑vitro or in‑vivo scientific research, provided it is not marketed with therapeutic claims.

 Do you ship Survodutide to France, Germany, Spain, Sweden, Italy, or the USA?
Absolutely. We ship across the EU and USA from our UK warehouse. Wholesale pricing is available for bulk orders.

Documentation, COA, and Quality Information

Professional buyers may request available documentation before discussing supply. This section should link directly to your COA page.

Suggested Quality Message

At Wuhan Top Miracle Peptides, verified buyers may contact our team to request available documentation, batch information, COA details, purity-related information, storage notes, and supply requirements for Survotitude. Documentation availability may vary by product, batch, country, and buyer qualification.

• Product label verification
• Storage and handling notes where legally appropriate
• Business contact details
• Shipping eligibility notice
• Reuters Survotitude Phase III reporting
  Google Search Central
  MHRA medicine advertising guidance
  ASA/CAP medicine and health product advertising rules

Professional Supply Regions For Survotitude

Wuhan Top Miracle Peptides supports wholesale and professional product enquiries across multiple regions.

Enquiry Regions

• United Kingdom
• France
• Germany
• Spain
• Sweden
• Italy
• USA
• Wider Europe

Survotitude

From appetite regulation and energy expenditure to hepatic lipid oxidation and lean mass preservation, Survodutide research peptide provides a well‑characterised, balanced dual agonist tool for advanced metabolic research. Its unique GLP‑1R/GCGR activation profile — supported by peer‑reviewed publications, clinical trial data, and a distinct advantage over single‑receptor compounds — makes it an essential addition to any laboratory studying obesity, MASH, or metabolic dysfunction.

By choosing high‑purity, lab‑verified Survodutide research peptide from Wuhan Top Miracle Peptides, you ensure that your research is built on a foundation of quality, reproducibility, and scientific integrity.

Ready to advance your metabolic research with Survodutide? Browse our product catalogue, request a wholesale quote, or contact our support team today to discuss your laboratory’s needs. Place your order now and receive laboratory‑ready, GMP‑quality Survodutide delivered directly to your facility in the UK, EU, or USA.